Drug Profile
Forodesine - Mundipharma International
Alternative Names: BCX-1777; Fodosine; Forodesine hydrochloride; Immucillin-H; MundesineLatest Information Update: 14 Apr 2021
Price :
$50
*
At a glance
- Originator Albert Einstein College of Medicine; Industrial Research Limited
- Developer BioCryst Pharmaceuticals; Mundipharma International
- Class Antineoplastics; Antipsoriatics; Purine nucleosides; Pyrimidinones; Small molecules
- Mechanism of Action Immunosuppressants; Purine nucleoside phosphorylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Peripheral T-cell lymphoma
- No development reported Chronic lymphocytic leukaemia
- Discontinued Cutaneous T-cell lymphoma; Haematological malignancies
Most Recent Events
- 14 Apr 2021 Discontinued - Phase-I for Haematological malignancies (Recurrent, Second-line therapy or greater) in Japan (PO) (Mundipharma pipeline, April 2021)
- 14 Apr 2021 Discontinued - Phase-II for Chronic lymphocytic leukaemia (Second-line therapy or greater) in USA (PO) (Mundipharma pipeline, April 2021)
- 14 Apr 2021 Discontinued - Phase-II for Cutaneous T-cell lymphoma (Second-line therapy or greater) in USA, Australia, Switzerland, Austria, Finland, Italy, France, Germany, Spain and United Kingdom (PO) (Mundipharma pipeline, April 2021)